



ASPARAGINASE IN THE TREATMENT OF PEDIATRIC ALL/LBL WITH A FOCUS ON Rylaze®

Featuring Dr. Ravi Shah from Alberta Children's Hospital

This session will cover the basics of leukemia and lymphoma, followed by an in-depth review of the key role of asparaginase in ALL treatment, including hypersensitivity reactions, and hypothetical case examples.

Lastly, Dr. Shah will provide an overview of the use of Rylaze in ALL/LBL treatment, including safety and efficacy data.

LEARNING OBJECTIVES:

- Understand the role of asparaginase in B cell leukemia/lymphoma
- Understand hypersensitivity reactions due to asparaginase
- Understand the role of non-*E. coli* asparaginase
- Understand Rylaze's safety and efficacy profile



If already registered, scan the QR code or visit the portal at <https://jazzpharma.impetusdigital.com/> to get started!

NOT REGISTERED?

Get started by contacting your Jazz Representative.

ALL: acute lymphoblastic leukemia; LBL: lymphoblastic lymphoma

© 2024 Jazz Pharmaceuticals, Inc. All rights reserved.

Rylaze® is a registered trademark of Jazz Pharmaceuticals plc or its subsidiaries.

CA-ASN-2400023

RYLAZE®
crisantasase recombinant



Jazz Pharmaceuticals